Johnson & Johnson Innovative Medicine

RYBREVANT^® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

Johnson & Johnson receives FDA approval for IMAAVY^TM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

U.S. FDA approves TREMFYA^® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

Johnson & Johnson closes landmark Intra-Cellular Therapies, Inc. acquisition to solidify neuroscience leadership

Areas of focus

Our transformational medicines are developed with rigorous science and unwavering compassion to provide the greatest impact for patients. We create new and groundbreaking medicines to change the future of health. Patients inform and inspire our science-based innovations. By exploring new pathways and methods, we stay ahead of diseases and find cures. Our scientists and researchers are pioneering the path from lab to life and championing patients each step of the way.

Oncology

March 20, 2024

Immunology

April 2, 2024

Neuroscience

April 2, 2024

Cardiopulmonary

August 28, 2024

At Johnson & Johnson, we are leading where medicine is going, with a relentless focus on bringing transformational medical innovation to patients who are waiting. Our team’s deep expertise and global reach are helping us reimagine how devastating diseases are treated and cured, delivering hope and better care for millions of patients and their families around the world.”

Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine,
Johnson & Johnson